Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 3,056 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Colon Clear all
Completed Phase 2 Interventional Results available

Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver

NCT03403634
View directory record Official record
Conditions
Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Celecoxib, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b, Rintatolimod
Drug · Other · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 31, 2026, 4:13 PM EDT
Terminated Phase 1 Interventional

A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

NCT06448364
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer, Melanoma
Interventions
PF-07329640, sasanlimab, bevacizumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 31, 2026, 4:13 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer

NCT01389830
View directory record Official record
Conditions
Advanced Cancers
Interventions
Telephone Survey
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 31, 2026, 4:13 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

NCT06055439
View directory record Official record
Conditions
Neuroendocrine Tumors, Colorectal Cancer, Gastric Cancer
Interventions
CHM-2101 CAR-T cells
Biological
Lead sponsor
Chimeric Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 4:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Paired Promotion of Colorectal Cancer and Social Determinants of Health Screening

NCT04585919
View directory record Official record
Conditions
Colorectal Cancer, Social Determinants of Health
Interventions
Paired Screening Intervention
Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Boston, Massachusetts • Brockton, Massachusetts • Lowell, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 31, 2026, 4:13 PM EDT
Completed No phase listed Observational Results available

Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation

NCT04683744
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
Semi-structured interviews-Patients, Semi-structured interviews-Health system
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 31, 2026, 4:13 PM EDT
Completed Not applicable Interventional

Scalable Communication Modalities for Returning Genetic Research Results

NCT04407611
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer, Lynch Syndrome
Interventions
Online modality, Genetic counselor follow-up
Behavioral
Lead sponsor
Boston University
Other
Eligibility
40 Years and older · Female only
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 31, 2026, 4:13 PM EDT
Completed Not applicable Interventional

An mHealth Symptom Management Intervention for Colorectal Cancer Patients (mCOPE)

NCT04763174
View directory record Official record
Conditions
Colorectal Cancer
Interventions
mHealth Coping Skills Training for Symptom Management (mCOPE)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 31, 2026, 4:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Knowing One's Estimated Colorectal Cancer Risk Influence Screening Behavior?

NCT03819920
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Risk Assessment (CCRAT), Usual Care (UC)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 75 Years
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 31, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer

NCT01765582
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
5-fluorouracil, bevacizumab, capecitabine, irinotecan, folinic acid, oxaliplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
45
States / cities
Mobile, Alabama • Long Beach, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 31, 2026, 4:13 PM EDT
Recruiting Not applicable Interventional

An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response

NCT04796818
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Diffusion Weighted Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 31, 2026, 4:13 PM EDT
Recruiting Phase 1 Interventional

Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

NCT07095517
View directory record Official record
Conditions
Colorectal Cancer Prevention, Colorectal Adenoma
Interventions
Tirzepatide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 4:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

NCT03829410
View directory record Official record
Conditions
Metastatic Colorectal Cancer, KRAS Gene Mutation
Interventions
Onvansertib, Bevacizumab, FOLFIRI
Drug · Biological
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 31, 2026, 4:13 PM EDT
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth

NCT01632020
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Placebo, Metformin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 31, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors

NCT01765790
View directory record Official record
Conditions
Metastatic Adenocarcinoma of the Colon or Rectum, Malignant Solid Tumors
Interventions
Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Scottsdale, Arizona • Sarasota, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 31, 2026, 4:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Colorectal Cancer Screening Intervention Study

NCT06424197
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Racial group-targeted messages, Explicit Commitment
Other
Lead sponsor
Oakland University
Other
Eligibility
45 Years to 80 Years
Enrollment
799 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 31, 2026, 4:13 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Gluteal Squeeze for Left Colon Distension

NCT04827485
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Gluteal squeeze, No squeeze
Other
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 31, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

NCT03082209
View directory record Official record
Conditions
Advanced Solid Tumors, Cancer, Hematologic Malignancies
Interventions
ABBV-621, Venetoclax, Bevacizumab, FOLFIRI
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
New Haven, Connecticut • Chicago, Illinois • Harvey, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 31, 2026, 4:13 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Atorvastatin ± Aspirin in Lynch Syndrome Syndrome

NCT04379999
View directory record Official record
Conditions
Lynch Syndrome
Interventions
Atorvastatin 20mg, Atorvastatin 20mg AND Aspirin 325 mg
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 31, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

NCT03829436
View directory record Official record
Conditions
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
Interventions
Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab
Drug
Lead sponsor
Tempest Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 31, 2026, 4:13 PM EDT
Completed Phase 2 Interventional

Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer

NCT00077298
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
cetuximab, bevacizumab, irinotecan hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 31, 2026, 4:13 PM EDT
Active, not recruiting Phase 1 Interventional

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

NCT04117087
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
KRAS peptide vaccine, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 31, 2026, 4:13 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Promoting Colorectal Cancer Screening in Rural Emergency Departments

NCT03473587
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Motivational interview, Standard of care
Behavioral
Lead sponsor
University of Kentucky
Other
Eligibility
50 Years and older
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Morehead, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 31, 2026, 4:13 PM EDT